Omeros Corporation ( (OMER) ) has released its Q3 earnings. Here is a breakdown of the information Omeros Corporation presented to its investors.
Omeros Corporation is a biopharmaceutical company engaged in the discovery, development, and commercialization of innovative therapeutics for various immunologic disorders, complement-mediated diseases, cancers, and addictive disorders. The company’s primary focus is on advancing its lead MASP-2 inhibitor, narsoplimab, and other promising drug candidates through clinical trials.
